Study Title: Saccharomyces boulardii Combined with Triple Therapy for H. pylori Infection
Key Findings:
A clinical trial evaluated the effectiveness of combining Saccharomyces boulardii powder with triple therapy for eradicating H. pylori infection in patients with non-ulcer dyspepsia. The study included 144 patients and monitored microbial composition, eradication rates, symptom alleviation, and adverse reactions.
Results:
The combination of Saccharomyces boulardii with triple therapy showed promising results, with a higher eradication rate of 93.18% in the BRAC group compared to 75% in the SRAC group and 65.2% in the RAC group. Patients receiving Saccharomyces boulardii treatment also experienced a reduction in initial dyspepsia symptoms.
Practical Solutions and Value:
Combining Saccharomyces boulardii with triple therapy demonstrated notable efficacy in eradicating initial H. pylori infections among non-ulcer dyspepsia patients. This approach also showed advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.
Importance of Clinical Trials:
Clinical trials play a crucial role in developing safe and effective treatments, and it’s essential to translate their benefits into everyday medical practice.
Our AI-Driven Platform:
DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, helping to streamline operations and improve patient outcomes.
Streamlining Healthcare Operations:
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
AI-Powered Workflow Enhancement:
By using AI, clinics can enhance their workflows, reduce paper routines, and improve patient outcomes. Learn more about how we can help at aidevmd.com.
